Overview

Sacituzumab Govitecan In TNBC

Status:
Active, not recruiting

Trial end date:
2025-10-30

Target enrollment:

Participant gender:

Summary

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: - Sacituzumab govitecan (SG) - Pembrolizumab (combination therapy with SG)

Phase:

Phase 2

Details

Lead Sponsor:

Aditya Bardia

Collaborators:

Gilead Sciences
Immunomedics, Inc.

Treatments:

Camptothecin
Immunoconjugates
Pembrolizumab